Caris Life Sciences, Inc.

Caris Life Sciences, Inc. (CAI) priced its initial public offering on Jun 20, 2025 at $21.00 per share, above its $19.00–$20.00 range, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $5.84B. BofA Securities was lead-left underwriter, joined by J.P. Morgan, Goldman Sachs and Citigroup and others. Latham & Watkins advised the company and Cooley advised the underwriters.

Caris Life Sciences, Inc. is an AI TechBio company that develops and commercializes precision medicine solutions using comprehensive molecular information and machine learning algorithms, with an initial focus on oncology, serving clinical, academic and biopharma markets.

Status

IPO

Ticker

CAI

Exchange

Nasdaq Global Select

Priced

Jun 20, 2025

IPO price

$21.00

Price range

$19.00–$20.00

Market cap at IPO price

$5.84B

First filed

May 23, 2025

Underwriters

BofA Securities, J.P. Morgan, Goldman Sachs, Citigroup, TD Cowen, Evercore ISI, Guggenheim, BTIG, Wolfe Research and Nomura

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Healthcare

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.